Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
RegulatoryWatchMinormateriality 56 out of 100
What happened
FactIntimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ref.: Update in respect of Arbitration Proceeding of Unitop Chemicals Private Limited. share purchase agreement (“SPA”) entered into by Rossari Biotech Limited (“Company”) on June 02,.
Why it matters
CapitSignal interpretationLitigation creates a contingent liability that is not in reported profit until it crystallises.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
DelayedEarlierQ4 FY26
we should see this part of this ramp-up happening this year and a full-scale premix facility capacity enhancement in the next year.
NowQ4 FY26
The CAPEX plan for this year would be I think anything between Rs. 50 crore to Rs. 75 crore, that is the plan.
Change
FactTimeline delay
Implication
CapitSignal interpretationThe earlier statement indicated a full-scale capacity enhancement would happen next year, while the current statement suggests a delay in the CAPEX plan for this year with a specific budget range.confidence 90%
Watch next
Fact- Amount claimed against the company
- Whether a provision has been made
- Next hearing or order date
- the other capex which we have announced, they are going to come over the next, about a year or so. (management committed by H1 FY27)
- I think we should be at a level of at least twice of what we currently are. (management committed by FY25)
Evidence
- Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(opens the original filing in a new tab)
- Earlier statement · Q4 FY26
- Latest statement · Q4 FY26
- Earlier statement · Q4 FY25
How CapitSignal classified this
- Reasoning:
- LITIGATION base 56; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%